CytoDyn Inc.
Other OTCTotal Valuation
CytoDyn Inc. carries a market capitalization of 273.95M, placing it among publicly traded companies globally. Its enterprise value stands at 420.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 273.95M |
| Enterprise Value | 420.39M |
Share Statistics
CytoDyn Inc. currently has 1.25B shares outstanding.
| Shares Outstanding | 1.25B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CytoDyn Inc. trades at a trailing price-to-earnings ratio of 153.92.
| PE Ratio | 153.92 |
| PS Ratio | N/A |
| PB Ratio | -0.46 |
| P/TBV Ratio | -4.22 |
| P/FCF Ratio | -47.02 |
| P/OCF Ratio | -46.20 |
Enterprise Valuation
On an enterprise value basis, CytoDyn Inc. trades at an EV/EBITDA multiple of 43.43 and an EV/FCF ratio of 277.85.
| EV / Sales | N/A |
| EV / EBITDA | 43.43 |
| EV / EBIT | 43.51 |
| EV / FCF | 277.85 |
Financial Position
CytoDyn Inc. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -28.47, indicating conservative leverage, while an interest coverage ratio of 2.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.25 |
| Quick Ratio | 0.20 |
| Debt / Equity | -28.47 |
| Debt / EBITDA | 2.82 |
| Interest Coverage | 2.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 26.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1.01 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CytoDyn Inc.'s stock has declined approximately -34.40472% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -34.40472% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.28 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached 9.68M, while operating income came in at 9.66M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | 9.66M |
| Pretax Income | 3.75M |
| Net Income | 3.75M |
| EBITDA | 9.68M |
| EBIT | 9.66M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
CytoDyn Inc. holds 11.90M in cash and equivalents against 27.34M in total debt, resulting in a net debt position of 15.30M. Total book value stands at -886.54M, with working capital of -52.64M providing operational flexibility.
| Cash & Cash Equivalents | 11.90M |
| Total Debt | 27.34M |
| Net Debt | 15.30M |
| Equity (Book Value) | -886.54M |
| Book Value Per Share | -0.74 |
| Working Capital | -52.64M |
Cash Flow
CytoDyn Inc. produced -8.76M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.76M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.76M |
| FCF Per Share | -0.01 |
Dividends & Yields
The company's payout ratio of -42.34 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -42.34 |
| Shareholder Yield | -2.68 |
| FCF Yield | -2.13 |
Scores
CytoDyn Inc. posts an Altman Z-Score of -68.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -68.47 |